OBJECTIVE: To observe the effect of Sancaijiangtang powders on plasma @entity842 and @entity2232 levels. We sought to identify the common pathological link and mechanism of action for Traditional Chinese medicine in @entity6 and @entity1294 , and to explicate the material basis for treating the different diseases with the same method in Traditional Chinese Medicine. METHODS: In total, 168 @entity1 with @entity6 and @entity1294 were enrolled in the study, and randomly divided into two groups by simple randomization. @entity1 in the treatment group received oral Sancaijiangtang powders with @entity12098 three times daily, while @entity1 in the control group received @entity12098 alone. The treatment course was for 12 weeks. Mini-mental state examinations (Chinese version) and Montreal Cognitive Assessments (Beijing version) were performed, and fasting plasma @entity413 , fasting insulin, hemoglobin A1c, homeostasis model assessment of insulin resistance, plasma @entity842 and @entity2232 levels were measured before and after the treatment. RESULTS: The post-treatment levels for all measurements in both groups were better than pre-treat- ment levels (P < 0.05). The post-treatment levels for all measurements in the treatment group were better than the levels measured in the control group (P < 0.05). CONCLUSION: @entity6 and @entity1294 have common pathological mechanisms for insulin resistance and endothelium dysfunction. Sancaijiangtang powders could improve the release of @entity842 and inhibit the secretion of @entity2232 . Therefore, the material basis exists for treating the different diseases with the same method in Traditional Chinese Medicine.

Effect of Sancaijiangtang on plasma @entity842 and XXXX levels in @entity1 with @entity6 and vascular demen- tia: a single-blind randomized controlled trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['type 2 diabetes mellitus', 'Type 2 diabetes mellitus'] @entity2232 :: ('1906', 'Gene') :: ['endothelin-1'] @entity1294 :: ('MESH:D015140', 'Disease') :: ['vascular dementia'] @entity12098 :: ('MESH:C060836', 'Chemical') :: ['pioglitazone hydrochloride'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2232 :: (1906,Gene) :: ['endothelin-1']
